(Q39561108)

English

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191).

scientific article published on April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

13 September 2017

Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). (English)

1 reference

Europe PubMed Central

13 September 2017

Hepatitis C virus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Ingrid Imhof

1

1 reference

Europe PubMed Central

13 September 2017

Peter Simmonds

2

1 reference

Europe PubMed Central

13 September 2017

language of work or name

0 references

publication date

1 April 2011

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

53

1 reference

Europe PubMed Central

13 September 2017

4

1 reference

Europe PubMed Central

13 September 2017

1090-1099

1 reference

Europe PubMed Central

13 September 2017

The natural history of hepatitis C virus (HCV) infection

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

The neglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Comparison of HCV NS3 protease and NS5B polymerase inhibitor activity in 1a, 1b and 2a replicons and 2a infectious virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Short-term antiviral efficacy of BILN 2061, a hepatitis C virus serine protease inhibitor, in hepatitis C genotype 1 patients.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Antiviral efficacy of NS3-serine protease inhibitor BILN-2061 in patients with chronic genotype 2 and 3 hepatitis C.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Rapid decline of viral RNA in hepatitis C patients treated with VX-950: a phase Ib, placebo-controlled, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Development of an intergenotypic hepatitis C virus (HCV) cell culture method to assess antiviral susceptibilities and resistance development of HCV NS3 protease genes from HCV genotypes 1 to 6

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Complete replication of hepatitis C virus in cell culture

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Construction and characterization of infectious intragenotypic and intergenotypic hepatitis C virus chimeras

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Relative Replication Capacity and Selective Advantage Profiles of Protease Inhibitor-Resistant Hepatitis C Virus (HCV) NS3 Protease Mutants in the HCV Genotype 1b Replicon System

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Genetic diversity and response to IFN of the NS3 protease gene from clinical strains of the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

A wide range of NS3/4A protease catalytic efficiencies in HCV-infected individuals

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Development of a replicon-based phenotypic assay for assessing the drug susceptibilities of HCV NS3 protease genes from clinical isolates

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Rapid emergence of protease inhibitor resistance in hepatitis C virus

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Characterization of resistance mutations against HCV ketoamide protease inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Transmission and disease association of Kaposi's sarcoma-associated herpesvirus: recent developments

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

1 reference

https://api.crossref.org/works/10.1002%2FHEP.24172

21 January 2018

Identifiers

10.1002/HEP.24172

1 reference

Europe PubMed Central

13 September 2017

1 reference

Europe PubMed Central

13 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39561108&oldid=1540344274"